Trispecific WuXi Biologics a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a groundbreaking partnership with Candid Therapeutics, Inc. (“Candid”). Candid is a clinical-stage biotechnology firm aiming to lead advancements in T-cell engager therapies for autoimmune and…
Astellas Pharma recently announced the approval Gastric Cancer of VYLOYTM (zolbetuximab) by China’s National Medical Products Administration (NMPA) for first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.…
Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies for patients with RAS-addicted cancers, recently announced the successful closing of its upsized underwritten public offering. The offering comprised 16,576,088 shares of common stock, priced at $46.00 per share,…
WuXi AppTec Recognized for Its Continued Commitment to Environmental, Social, and Governance Excellence WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its inclusion in the 2024 Dow Jones Sustainability Indices (DJSI) for the…
OS Therapies Announces $6 Million Private Placement to Fund Clinical Development of OST-HER2 for Osteosarcoma and Other Cancer Indications OS Therapies, a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies and antibody-drug conjugates, has successfully closed a private placement…
The Future of Cancer Immunotherapy: Market Insights 2025-2029 The report titled “Cancer Immunotherapy Market 2025-2029 – Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides” has been added to ResearchAndMarkets.com’s offerings. It aims to shed…
Merck, a leading science and technology company, announced plans to invest over €70 million in constructing a new Advanced Materials Development Center (AMDC) at its Shizuoka site in Japan. This brings Merck’s total investment in Shizuoka to over €120 million…
The World Health Organization WHO Academy in Lyon, France, officially opened its doors yesterday with a grand inauguration ceremony. The event was graced by French President Emmanuel Macron, WHO Director-General Dr. Tedros Adhanom Ghebreyesus, and a distinguished assembly of health…
The global market for Antisense & RNAi therapeutics is poised for significant growth, with projections estimating its value at US$5.4 billion in 2024. This market is expected to expand at a compound annual growth rate (CAGR) of 17.8%, reaching a…
Crown Bioscience, a leading global contract research organization (CRO) based in the United States and a part of JSR Life Sciences and Japan’s JSR Corporation, has been awarded the prestigious 2024 Fierce CRO Award for Excellence in Client Service and…
Silal and Bayer have reinforced their commitment to agricultural innovation in the UAE with the signing of a comprehensive Memorandum of Understanding (MoU) at the World Agri-Tech Innovation Summit in Dubai. This collaboration builds upon their partnership formed in December…
Biogen has appointed Tim Power as Vice President and Head of Investor Relations, effective December 9, 2024. In this role, Mr. Power will report directly to Michael McDonnell, the company’s Executive Vice President and Chief Financial Officer. I am excited…